Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0910 BTS47 Hamburg podcast
BioCentury & Getty Images

Back to School 2020

Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview

Poor preparedness for this pandemic calls for a commitment to ensure a better response in the future, says Hamburg

Poor preparedness for this pandemic calls for a commitment to ensure a better response in the future, says former FDA Commissioner Margaret Hamburg.

Sep 11, 2020 | 2:37 AM GMT

The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served as FDA Commissioner in 2009-15, told BioCentury.

“We've seen the ecosystem of medical product development behaving very differently in the context of COVID, and I think there are important lessons to be learned and applied going forward,” said Hamburg in a BioCentury Back to School audio interview. The conversation was one of a series of BioCentury’s Back to School 2020 audio interviews with industry leaders (see Cover Story: “The Imperative of COVID-19”).

One of those lessons, Hamburg said, is the need to break the “alarm and hit the snooze button phenomenon” that

Read the full 2000 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE